2023
Role of metformin in the management of type 2 diabetes: recent advances.
Gonzalez-Lopez C, Wojeck B. Role of metformin in the management of type 2 diabetes: recent advances. Polish Archives Of Internal Medicine 2023, 133 PMID: 37317976, DOI: 10.20452/pamw.16511.Peer-Reviewed Original ResearchConceptsType 2 diabetesAntidiabetic medicationsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCardio-renal protectionCotransporter 2 inhibitorsFirst-line agentsFirst-line therapyPolycystic ovary syndromeRole of metforminRisk of hypoglycemiaTreatment of obesityManagement of diabetesBlood glucose levelsMechanism of actionInitial therapyWay diabetesGestational diabetesOvary syndromeHeart failureRenal diseaseInsulin resistanceInsulin sensitivityReceptor agonist
2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing 2022, 27: 669-672. PMID: 35596030, PMCID: PMC10212814, DOI: 10.1007/s11325-022-02594-2.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaIncident obstructive sleep apneaAtherosclerotic CV diseaseVERTIS CVSleep apneaMultivariable Cox proportional hazards regression modelsIncidence of OSACox proportional hazards regression modelBaseline obstructive sleep apneaMajor adverse CV eventsProportional hazards regression modelsCV outcome trialsEffect of ertugliflozinInvestigator-reported eventsVERTIS-CV trialAdverse CV eventsSleep apnea syndromeRelative risk reductionHazards regression modelsType 2 diabetesCV eventsCV diseasePrimary endpointInhibitor empagliflozinOutcome trials
2021
Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.
Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexObstructive sleep apneaPolysomnographic phenotypeIncident T2DMRisk of T2DMPredictive valueSleep apneaBlood glucoseRisk factorsCardiovascular diseaseMild obstructive sleep apneaIncident type 2 diabetesMultivariable-adjusted regression modelsCox proportional hazards regressionNew physician diagnosisT2DM risk predictionIncident cardiovascular diseaseIncident type 2Body mass indexProportional hazards regressionT2DM risk factorsBehavioral risk factorsType 2 diabetesMale veteran populationRisk regression models
2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatients